• Cyclodextrin-Induced Cholesterol Depletion Attenuates TRPV1/

  2026-05-15

  This study demonstrates that specific cyclodextrin derivatives can inhibit TRPV1- and TRPA1-mediated nociception by selectively depleting membrane cholesterol in sensory neurons. The work introduces a novel, non-antagonist mechanism for peripheral analgesia, potentially guiding new approaches for pain research and intervention.

• Ertugliflozin (PF-04971729): Selective SGLT2 Inhibitor Evide

  2026-05-15

  Ertugliflozin (PF-04971729) is a highly selective SGLT2 inhibitor used in diabetes mellitus research and renal glucose transport studies. This article details its atomic mechanism, validated applications, and benchmarked efficacy in glycemic control, cardiovascular protection, and anti-inflammatory activity.

• Bazedoxifene: Applied SERMs for Osteoporosis Research Excell

  2026-05-14

  Bazedoxifene, a third-generation selective estrogen receptor modulator, offers unparalleled tissue-selectivity and robust in vitro/in vivo performance for bone mineral density research. This article delivers actionable protocols, advanced workflow tips, and troubleshooting strategies to maximize data quality in osteoporosis and estrogen receptor pathway studies.

• Ertugliflozin and Cardiovascular Outcomes in Type 2 Diabetes

  2026-05-14

  The VERTIS CV trial rigorously evaluated the cardiovascular and renal safety profile of Ertugliflozin (PF-04971729) in patients with type 2 diabetes and atherosclerotic cardiovascular disease. The study found that Ertugliflozin was noninferior to placebo for major adverse cardiovascular events, supporting its role in advanced diabetes mellitus research and translational protocols.

• Berberine Hydrochloride: Mechanisms & Benchmarks for Metabol

  2026-05-13

  Berberine hydrochloride is a bioactive isoquinoline alkaloid with established antibacterial, metabolic, and apoptosis-modulating effects. Its AMPK activation and LDL receptor upregulation underpin applications in metabolic disease research. This article details mechanism, evidence, and workflow integration, extending current literature with verified, granular facts.

• BIRB 796 (Doramapimod): Dual-Action p38α MAPK Inhibition Unv

  2026-05-13

  Discover the dual-action mechanism of BIRB 796 (Doramapimod), a highly selective p38α MAPK inhibitor. This article uniquely explores new insights into kinase dephosphorylation, providing advanced guidance for inflammation and apoptosis research.

• Cell Counting Kit-8 (CCK-8): Precision Cell Viability in Act

  2026-05-12

  The Cell Counting Kit-8 (CCK-8) empowers researchers with a rapid, sensitive solution for quantifying cell proliferation and cytotoxicity. Its water-soluble WST-8 chemistry streamlines experimental workflows and delivers reproducible data, even in complex disease models such as rheumatoid arthritis or cancer. Discover how to harness CCK-8's unique advantages for robust experimental results.

• A Drug-Sensitized Yeast Platform for mTOR Inhibitor Discover

  2026-05-12

  Breen et al. (2025) present a drug-sensitized yeast system that dramatically increases the sensitivity and specificity of mTOR/TOR inhibitor detection, enabling rapid identification of candidate compounds with geroprotective or anti-cancer potential. Their findings clarify the selectivity of known and novel molecules, including the non-inhibitory profile of Canagliflozin in this context.

• Distinct Volatile Profiles of Chuanxiong Cortex and Pith in

  2026-05-11

  This study systematically differentiates the volatile components and pharmacological targets of Ligusticum chuanxiong's rhizome cortex and pith in the context of coronary heart disease (CHD) prevention. By integrating SPME-GC×GC-MS with network pharmacology and molecular docking, the research reveals unique bioactive profiles and pathway associations for each plant part, offering deeper mechanistic insight for precision herbal interventions.

• Abiraterone Acetate: CYP17 Inhibitor Workflows in Prostate C

  2026-05-11

  Harness the translational power of abiraterone acetate, a leading CYP17 inhibitor, to dissect androgen biosynthesis and resistance mechanisms in advanced 3D prostate cancer models. This guide delivers actionable workflows, protocol enhancements, and critical troubleshooting to maximize reproducibility and insight in prostate cancer research.

• Weight Loss Restores Intestinal Stretch-Induced Satiety Mech

  2026-05-10

  This study demonstrates that obesity impairs, but weight loss restores, the ability of intestinal stretch to suppress food intake and improve glucose tolerance in mice. The findings challenge the centrality of GLP-1 signaling in these processes and have significant implications for metabolic disease research and therapeutic strategies.

• Omeprazole (A2845): Protocols for H+,K+-ATPase Inhibition St

  2026-05-09

  Omeprazole (SKU A2845) is a high-purity H+,K+-ATPase inhibitor engineered for rigorous gastric acid secretion research and antiulcer activity studies. It is not intended for diagnostic or therapeutic use, and care should be taken to avoid extrapolating beyond preclinical and mechanistic research boundaries.

• Trelagliptin Succinate Workflows: Applied Protocols in T2DM

  2026-05-08

  Trelagliptin succinate (SYR-472 succinate) is more than a once-weekly DPP-4 inhibitor—its selective modulation of metabolic and osteogenic pathways enables cutting-edge research in diabetes and bone biology. This article details actionable protocols, troubleshooting strategies, and novel insights inspired by recent breakthroughs, helping researchers maximize reproducibility and impact.

• High-Throughput Blood-Brain Barrier Model: Predictive Power

  2026-05-08

  Hu et al. introduce a robust, high-throughput in vitro blood-brain barrier (BBB) model leveraging LLC-PK1-MOCK/MDR1 cells and lysosomal trapping correction to accurately predict CNS drug permeability. Their approach improves early-stage screening and correlates in vitro permeability with in vivo brain distribution, streamlining candidate selection for neurological therapeutics.

• Canagliflozin: SGLT2 Inhibitor Workflows for Renal Research

  2026-05-07

  Canagliflozin, a potent SGLT2 inhibitor, is reshaping metabolic and renal disease research by enabling reproducible modulation of glucose transport and mitochondrial remodeling in proximal tubular cells. This guide delivers stepwise protocols, troubleshooting insights, and evidence-backed benchmarks for leveraging Canagliflozin in diabetes, kidney, and mitochondrial studies.

15963 records 1/1065 page Next 12345 下5页 Last page